Virax Biolabs to Sell Up to $1.45M in Shares via ATM Offering
Ticker: VRAX · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1,455,029 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: at-the-market, equity-offering, capital-raise, dilution-risk
TL;DR
**Virax Biolabs just set up a $1.45M 'at-the-market' stock sale, meaning more shares could hit the market.**
AI Summary
On January 22, 2024, Virax Biolabs Group Limited entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to potentially sell up to $1,455,029 worth of its ordinary shares. This ATM offering allows Virax Biolabs to raise capital by selling shares directly into the market over time, rather than through a single large offering. For investors, this means potential dilution as more shares could be issued, which might put downward pressure on the stock price, but it also provides the company with flexible access to funding for its operations.
Why It Matters
This ATM offering provides Virax Biolabs with a flexible way to raise capital, but it also introduces the risk of share dilution for existing shareholders, potentially impacting the stock's value.
Risk Assessment
Risk Level: medium — The ATM offering creates potential for share dilution, which can negatively impact existing shareholders, but also provides the company with necessary capital.
Analyst Insight
A smart investor would monitor the volume of shares sold through this ATM offering to gauge the extent of potential dilution and its impact on the stock price, while also considering the company's use of the raised capital.
Key Numbers
- $1,455,029 — Aggregate Offering Amount (The maximum value of ordinary shares Virax Biolabs may sell through the ATM offering.)
- 0.001 — Par Value per Share (The nominal value of each ordinary share of Virax Biolabs Group Limited.)
Key Players & Entities
- Virax Biolabs Group Limited (company) — the registrant entering the sales agreement
- H.C. Wainwright & Co., LLC (company) — the sales agent for the offering
- $1,455,029 (dollar_amount) — the aggregate offering amount of ordinary shares
- January 22, 2024 (date) — the date the Sales Agreement was entered into and the prospectus supplement was filed
- December 15, 2023 (date) — the date of the accompanying base prospectus
Forward-Looking Statements
- Virax Biolabs will utilize a significant portion of the $1,455,029 ATM offering to fund ongoing operations or research and development. (Virax Biolabs Group Limited) — medium confidence, target: 2024-12-31
- The stock price of Virax Biolabs will experience short-term volatility due to the potential for share dilution from the ATM offering. (Virax Biolabs Group Limited) — medium confidence, target: 2024-06-30
FAQ
What is the purpose of the At The Market Offering Agreement Virax Biolabs Group Limited entered into?
Virax Biolabs Group Limited entered into the At The Market Offering Agreement to offer and sell, from time to time, its ordinary shares having an aggregate offering amount of up to $1,455,029, through H.C. Wainwright & Co., LLC acting as its sales agent.
Who is the sales agent for this offering?
H.C. Wainwright & Co., LLC is acting as the sales agent for Virax Biolabs Group Limited in this At The Market Offering Agreement.
What is the maximum aggregate offering amount of ordinary shares that Virax Biolabs Group Limited may sell under this agreement?
The maximum aggregate offering amount of ordinary shares that Virax Biolabs Group Limited may sell under this agreement is up to $1,455,029.
When was the Sales Agreement entered into and the prospectus supplement filed?
The Sales Agreement was entered into and the prospectus supplement was filed on January 22, 2024.
Is Virax Biolabs Group Limited obligated to sell shares under this agreement?
No, Virax Biolabs Group Limited is not obligated to sell any shares under the Sales Agreement, as stated in the filing.
Filing Stats: 726 words · 3 min read · ~2 pages · Grade level 14.8 · Accepted 2024-01-22 17:28:36
Key Financial Figures
- $0.001 — s Agent, its ordinary shares, par value $0.001 per share (the “ Ordinary Shares
- $1,455,029 — g an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the S
Filing Documents
- 6-k_atm.htm (6-K) — 30KB
- vrax-ex5_1.htm (EX-5.1) — 57KB
- vrax-ex10_1.htm (EX-10.1) — 356KB
- 0000950170-24-006158.txt ( ) — 444KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: January 22, 2024 By: /s/ James Foster James Foster, Chief Executive Officer